SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
AARD

Aardvark Therapeutics, Inc. (NASDAQ:AARD)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.92-$0.08 (-7.74%)
 
Market cap
$20.2M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 13, 2025
Market Cap$20.20M-90.3%
Revenue (ttm)$0
Net Income-$72.76M-49.2%
EPS-$3.34-49.1%
Shares Out21.89M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume241,067
Open$1.00
Previous Close$1.00
Day's Range$0.90 - $1.04
52-Week Range$0.90 - $16.60
Beta3.81
AnalystsBuy
Price Target$2.40(+160.13%)
Earnings DateMar 22, 2027
-8.00% (1D)
No price history available.

About AARD

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.

Address
4370 La Jolla Village Drive, San Diego, CA, 92122, US
Market Cap
20 million
Employees
28
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$394.96K
Bought
$144.59K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Hold
1 Buy2 Hold0 SellAvg target $18.40 (+1894.4%)

3 firms rating AARD in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Sound
From AARD’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-7.74%
5 Days
-30.63%
1 Month
-76.64%
6 Months
-79.68%
1 Year
-90.29%

$AARD stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in AARD holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by AARD's directors and management

Net Shares Purchased by Insiders−80k−40k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

AARD Estimated quarterly lobbying spending

Source: U.S. Senate LDA

AARD Revenue by Segment

$223.00KTotal
Facilities-related and other allocated costs$215.00K96.41%
Unrealized (gains) losses on short-term investments$8.00K3.59%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New AARD patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to AARD from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in AARD

VTIVanguard Morningstar Total Stock Market ETF$417.75K
VXFVanguard Extended Market ETF$190.93K
IBBiShares Biotechnology ETF$90.21K
IWCiShares Micro-Cap ETF$35.18K
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF$20.00K
DXUVU.S. Vector Equity Portfolio ETF Class Shares$2.24K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from AARD’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
60
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
2
Sells
2
Buy Value
$144.59K
Distinct Buyers
2

Insider Score Trend Over Time

+0.0 since Sep 12
0255075100Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 27.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Sep 12Sep 23Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.03%
IBBQInvesco Nasdaq Biotechnology ETF0.00%
BIBProShares Ultra Nasdaq Biotechnology0.00%
IBBiShares Biotechnology ETF0.00%

Weight is the stock’s share of each fund’s holdings.